- UroToday Home
- Transformative Evidence
Transformative Evidence
PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos
Profound Study Discussion Videos
January 11, 2021
November 23, 2020
October 16, 2020
Publications
Peer-Reviewed Journal Articles and Abstracts
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent.
Read More
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers.
Read More
Conference Coverage
Conference Highlights from Recent Conference Coverage
SUO 2020: Results from the PROfound Study, A New Second Line Therapy for mCRPC
Presented by Maha H.A. Hussain, MD, FACP, FASCO
In the second Prostate Cancer session at this year’s Society of Urologic Oncology virtual annual meeting, Dr. Hussain discussed the role of PARP inhibitors, particularly Olaparib, in metastatic castration-resistant prostate cancer. Read More
EMUC 2020: A New Treatment Paradigm for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and BRCA1, BRCA2 or ATM Mutations, The PROfound Study
Presented by Karim Fizazi, MD, Ph.D
In an oral presentation in the New Trials Update session at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Karim Fizazi presented a discussion of the results of PROfound Study, Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound), examining the role of olaparib among patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA defect repair (DDR) mutations. Read More
ESMO Virtual Congress 2020: The Final Overall Survival (OS) Analysis From the PROfound Study and IPATential150, Ipatasertib Plus Abiraterone (abi) vs Placebo Plus Abi in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Invited Discussion
Presented by Henrik Grönberg, MD, PhD
(UroToday.com) Following the presentations from Dr. de Bono and Dr. Joaquin Mateo of the data from IPATential150 and PROfound, respectively, Dr. Henrik Grönberg provided an invited discussion of these data. He began by laying out a number of important topics to consider: 1. study population: is this representative of patients seen in the clinic today? 2. control group: are these patients getting the best treatment available? Read More
ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician’s Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration
Presented by Joaquin Mateo, MD
In 2016, Pritchard and colleagues reported that mutations in DNA-damage repair genes, particularly homologous recombination repair genes, were relatively common among patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Read More
ESMO Virtual Congress 2020: Exploring the Impact of Treatment Switching on the Interim Overall Survival Results of the PROfound Study
(UroToday.com) In the phase III PROfound study, olaparib lead to significantly longer radiographic progression-free survival compared with physician’s choice of next-generation hormonal agent (control) in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC) and alterations in homologous recombination repair (HRR) genes. Read More
ESMO Virtual Congress 2020: The Tolerability of Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene Alterations: The PROfound Study
(UroToday.com) In 2016, Pritchard and colleagues reported that mutations in DNA-damage repair genes, particularly homologous recombination repair genes, were relatively common among patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Read More
ASCO 2020: Impact of Olaparib vs Physician’s Choice of New Hormonal Agent on Burden of Pain in mCRPC: PROfound
Presented by Fred Saad, MD, FRCS
In the Phase III PROfound study, olaparib significantly improved radiographic progression-free survival (primary endpoint) versus physician’s choice of new hormonal agent (enzalutamide or abiraterone) in patients with mCRPC and homologous recombination repair (HRR) gene alterations. Read More
ASCO 2020: Health-Related Quality of Life for Olaparib versus Enzalutamide or Abiraterone in mCRPC with Homologous Recombination Repair Gene Alterations: PROfound
Presented by Antoine Thiery-Vuillemin, MD, PhD
The randomized Phase 3 PROfound trial showed that olaparib significantly prolonged radiographic progression-free survival compared with physician’s choice of new hormonal agent (enzalutamide or abiraterone) in men with mCRPC and HRR gene alterations, whose disease had progressed on prior new hormonal agent. Read More
ASCO GU 2020: Contemporary Clinical Impact of Genetic and Genomic Testing in Prostate Cancer
Presented by Elena Castro, MD, PhD
San Francisco, CA (UroToday.com) In this talk, Dr. Elena Castro gave an overview of the genomic landscape of advanced prostate cancer. It has been shown that in over 70% Read More
ASCO GU 2020: Next-Generation Sequencing (NGS) of Tumor Tissue from >4000 Men with mCRPC: The PROfound Phase III Study Experience
San Francisco, California (UroToday.com) Metastatic castration-resistant prostate cancer (mCRPC) is a molecularly heterogeneous disease, with between 20 and 25% of patients with mCRPC harboring deleterious alterations in DNA damage repair genes, including those with direct or indirect roles in homologous recombination repair (HRR). Read More
ESMO 2019: PROfound: Phase 3 Study of Olaparib vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations
Presented by Maha Hussain, MD
Barcelona, Spain (UroToday.com) Despite significant progress in systematic therapy, metastatic castration-resistant prostate cancer (mCRPC) continues to be a lethal disease. Read More
ESMO 2019: Invited Discussant - PROfound: A Phase 3 Study of Olaparib versus Enzalutamide or Abiraterone for mCRPC with Homologous Recombination Repair Gene Alterations
Presented by Eleni Efstathiou, MD, PhD
Barcelona, Spain (UroToday.com) Following oral presentation of the PROfound study of olaparib in metastatic castration-resistant prostate cancer (mCRPC) patients with selected homologous recombination repair defects in their tumors, Dr. Eleni Efstathiou discussed the findings and posed the question of whether this study should be considered practice-changing. Read More
ESMO 2019: Central, Prospective Detection of Homologous Recombination Repair Gene Mutations in Tumor Tissue from >4000 Men with mCRPC Screened for the PROfound Study
Barcelona, Spain (UroToday.com) A proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) have tumor cells harboring homologous recombination repair gene mutations that may confer sensitivity to poly ADP-ribose polymerase (PARP) inhibition. Read More